Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-03 00:00:00 ET · period of report 2023-02-01 · accession 0001209191-23-007012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-03 | 2023-02-01 | VRTX | WAGNER CHARLES F JR | EVP, CFO | A - Grant | $0.00 | +30.0K | 53.2K | +130% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-01 | A | A | 10,262 | $0.00 | 63,450 | D | — | — | (F2) Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. |
| 2 | Common | Common Stock | 2023-02-01 | A | A | 9,440 | $0.00 | 72,890 | D | — | — | (F3) Restricted stock unit award that vests in installments beginning on 02/10/2024. |
| 3 | Common | Common Stock | 2023-02-01 | A | A | 10,324 | $0.00 | 53,188 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. |